NO20031833L - Behandling av gastrointestinale stromatumorer - Google Patents

Behandling av gastrointestinale stromatumorer

Info

Publication number
NO20031833L
NO20031833L NO20031833A NO20031833A NO20031833L NO 20031833 L NO20031833 L NO 20031833L NO 20031833 A NO20031833 A NO 20031833A NO 20031833 A NO20031833 A NO 20031833A NO 20031833 L NO20031833 L NO 20031833L
Authority
NO
Norway
Prior art keywords
treatment
gastrointestinal stromal
stromal tumors
methylpiperazin
ylamino
Prior art date
Application number
NO20031833A
Other languages
English (en)
Other versions
NO20031833D0 (no
NO324948B1 (no
Inventor
Elisabeth Buchdunger
Renaud Capdeville
George Daniel Demetri
Sasa Dimitrijevic
Brian J Druker
Jonathan A Fletcher
Heikki Joensuu
Sandra L Silberman
David Tuveson
Michael C Heinrich
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22920224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20031833(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20031833D0 publication Critical patent/NO20031833D0/no
Publication of NO20031833L publication Critical patent/NO20031833L/no
Publication of NO324948B1 publication Critical patent/NO324948B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Farming Of Fish And Shellfish (AREA)
NO20031833A 2000-10-27 2003-04-24 Anvendelse av 4-(4-metylpiperazin-1-ylmetyl)-N-[4-metyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)fenyl]benzamid ved behandling av gastrointestinale stromatumorer. NO324948B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24381000P 2000-10-27 2000-10-27
PCT/EP2001/012442 WO2002034727A2 (en) 2000-10-27 2001-10-26 Treatment of gastrointestinal stromal tumors

Publications (3)

Publication Number Publication Date
NO20031833D0 NO20031833D0 (no) 2003-04-24
NO20031833L true NO20031833L (no) 2003-04-24
NO324948B1 NO324948B1 (no) 2008-01-07

Family

ID=22920224

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031833A NO324948B1 (no) 2000-10-27 2003-04-24 Anvendelse av 4-(4-metylpiperazin-1-ylmetyl)-N-[4-metyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)fenyl]benzamid ved behandling av gastrointestinale stromatumorer.

Country Status (25)

Country Link
US (1) US6958335B2 (no)
EP (1) EP1332137B1 (no)
JP (1) JP4386635B2 (no)
KR (1) KR100885129B1 (no)
CN (1) CN1276754C (no)
AT (1) ATE321556T1 (no)
AU (2) AU1826202A (no)
BR (1) BRPI0114870B8 (no)
CA (1) CA2424470C (no)
CY (1) CY1105055T1 (no)
CZ (1) CZ303944B6 (no)
DE (1) DE60118430T2 (no)
DK (1) DK1332137T3 (no)
ES (1) ES2260317T3 (no)
HU (1) HU229106B1 (no)
IL (2) IL155029A0 (no)
MX (1) MXPA03003703A (no)
NO (1) NO324948B1 (no)
NZ (1) NZ525254A (no)
PL (1) PL209733B1 (no)
PT (1) PT1332137E (no)
RU (1) RU2301066C2 (no)
SK (1) SK287335B6 (no)
WO (1) WO2002034727A2 (no)
ZA (1) ZA200302155B (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
BR0209647A (pt) * 2001-05-16 2004-07-27 Novartis Ag Combinação que compreende n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina e um agente quimioterapêutico
PT1401416E (pt) * 2001-06-29 2007-02-28 Ab Science Utilização de inibidores de c-kit para tratar doenças inflamatórias intestinais (dii)
US7700610B2 (en) * 2001-06-29 2010-04-20 Ab Science Use of tyrosine kinase inhibitors for treating allergic diseases
EP1434991B1 (en) * 2001-06-29 2007-10-17 AB Science New potent, selective and non toxic c-kit inhibitors
CA2452366A1 (en) * 2001-06-29 2003-01-16 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
CA2452169A1 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory diseases
CA2460845A1 (en) * 2001-09-20 2003-03-27 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
WO2003035050A2 (en) * 2001-09-20 2003-05-01 Ab Science Use of tyrosine kinase inhibitors for promoting hair growth
CA2477111A1 (en) * 2002-02-27 2003-09-04 Ab Science Use of tyrosine kinase inhibitors for treating cns disorders
FR2844452A1 (fr) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
CN100467064C (zh) * 2003-09-19 2009-03-11 诺瓦提斯公司 伊马替尼和米哚妥林在制备治疗胃肠道基质肿瘤药物中的应用
US20100210596A1 (en) * 2006-02-01 2010-08-19 Bluestone Jeffrey A Use of aminopyrimidine compounds in the treatment of immune disorders
US20080221132A1 (en) * 2006-09-11 2008-09-11 Xiong Cai Multi-Functional Small Molecules as Anti-Proliferative Agents
CA2662580C (en) * 2006-09-11 2013-05-21 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US20090082361A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched imatinib
CN101584696A (zh) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
WO2010120386A1 (en) 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
KR102061743B1 (ko) 2011-03-04 2020-01-03 뉴젠 세러퓨틱스 인코포레이티드 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
CN102918029B (zh) 2011-05-17 2015-06-17 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
EP2817030A1 (en) 2012-02-21 2014-12-31 Ranbaxy Laboratories Limited Stable dosage forms of imatinib mesylate
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
EP2877159B8 (en) 2012-07-27 2018-02-14 Izumi Technology, LLC. Efflux inhibitor compositions and methods of treatment using the same
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
US11285152B2 (en) 2017-07-20 2022-03-29 Kashiv Biosciences, Llc Stable oral pharmaceutical composition of imatinib
AU2019216351B2 (en) 2018-01-31 2024-07-25 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
EP3746059B1 (en) 2018-01-31 2026-03-04 Deciphera Pharmaceuticals, LLC Combination therapy for the treatment of gastrointestinal stromal tumors
WO2020185812A1 (en) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
EP4725489A2 (en) 2019-08-02 2026-04-15 OneHealthCompany, Inc. Treatment of canine cancers
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
FI4013412T3 (fi) 2019-08-12 2026-03-24 Deciphera Pharmaceuticals Llc Ripretinibi ruoansulatuskanavan stroomakasvaimien hoitoon
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
PL4084779T3 (pl) 2019-12-30 2025-02-24 Deciphera Pharmaceuticals, Llc Kompozycje 1-(4-bromo-5-(1-etylo-7-(metyloamino)-2-okso-1,2-dihydro-1,6-naftyrydyn-3-ylo)-2-fluorofenylo)-3-fenylomocznika
KR102535840B1 (ko) 2020-07-31 2023-05-23 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1528449A1 (ru) * 1985-06-05 1989-12-15 Центральный институт усовершенствования врачей Способ релаксации илеоцекального отдела кишечника
TW225528B (no) * 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
EP1117397A1 (en) * 1998-08-31 2001-07-25 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity

Also Published As

Publication number Publication date
PT1332137E (pt) 2006-07-31
US6958335B2 (en) 2005-10-25
ES2260317T3 (es) 2006-11-01
KR100885129B1 (ko) 2009-02-23
PL362148A1 (en) 2004-10-18
JP2004512328A (ja) 2004-04-22
ATE321556T1 (de) 2006-04-15
PL209733B1 (pl) 2011-10-31
JP4386635B2 (ja) 2009-12-16
HUP0301512A2 (hu) 2003-11-28
EP1332137A2 (en) 2003-08-06
EP1332137B1 (en) 2006-03-29
NZ525254A (en) 2006-02-24
CZ20031152A3 (en) 2004-04-14
BRPI0114870B8 (pt) 2021-05-25
NO20031833D0 (no) 2003-04-24
WO2002034727A3 (en) 2003-03-27
NO324948B1 (no) 2008-01-07
WO2002034727A2 (en) 2002-05-02
SK287335B6 (sk) 2010-07-07
SK5182003A3 (en) 2004-02-03
RU2301066C2 (ru) 2007-06-20
AU2002218262B2 (en) 2005-09-29
KR20030051656A (ko) 2003-06-25
CZ303944B6 (cs) 2013-07-10
MXPA03003703A (es) 2005-01-25
IL155029A0 (en) 2003-10-31
CN1276754C (zh) 2006-09-27
CA2424470A1 (en) 2002-05-02
US20040023976A1 (en) 2004-02-05
DE60118430D1 (de) 2006-05-18
BRPI0114870B1 (pt) 2020-06-16
DE60118430T2 (de) 2006-10-26
DK1332137T3 (da) 2006-07-17
HU229106B1 (en) 2013-07-29
CN1622808A (zh) 2005-06-01
HK1058193A1 (en) 2004-05-07
BR0114870A (pt) 2004-02-17
CY1105055T1 (el) 2010-03-03
ZA200302155B (en) 2004-04-22
CA2424470C (en) 2009-06-09
IL155029A (en) 2009-09-22
AU1826202A (en) 2002-05-06

Similar Documents

Publication Publication Date Title
NO20031833D0 (no) Behandling av gastrointestinale stromatumorer
TR200000060T2 (tr) Bir N-fenil-2-pirimidinamin türevinin kristal modifikasyonu ve yapım işlemleri ve kullanımı.
IL164678A (en) High-drug tablet containing 4– (4-methylpiprazine – 1-ylamethyl) -n - [(4-methyl-3– (4-pyridin-3-il) pyrimidine-2-ylamino) phenyl] -benzamide or compatible salt Its pharmaceutical and process for its preparation
TWI347186B (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
RU2003114752A (ru) Лечение желудочно-кишечных стромальных опухолей
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
ATE399555T1 (de) Behandlung der rheumatoiden arthritis mit imitanib
ATE468855T1 (de) Kombination von stickstoff-senf analogen und imatinib für die behandlung von chronischer lymphatischer leukämie
AU2003216621A8 (en) Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
IL171927A0 (en) Use of tyrosine kinase inhibitor to treat diabetes
BR0312242A (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida para o tratamento da fibrose pulmonar
AU2003209521A1 (en) Use of 4-(4-methylpiperazin-1-ylmethyl)-n(4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl)-benzamide for treating seminomas
WO2004103374A3 (en) Imatinib combinations for head and neck cancers
HK1097535A (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
NZ610401A (en) Inhibitors of the mutant form of kit

Legal Events

Date Code Title Description
MK1K Patent expired